185 related articles for article (PubMed ID: 22448988)
1. Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
Zhou H; Chen J; Meagher JL; Yang CY; Aguilar A; Liu L; Bai L; Cong X; Cai Q; Fang X; Stuckey JA; Wang S
J Med Chem; 2012 May; 55(10):4664-82. PubMed ID: 22448988
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
Zhou H; Aguilar A; Chen J; Bai L; Liu L; Meagher JL; Yang CY; McEachern D; Cong X; Stuckey JA; Wang S
J Med Chem; 2012 Jul; 55(13):6149-61. PubMed ID: 22747598
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
Chen J; Zhou H; Aguilar A; Liu L; Bai L; McEachern D; Yang CY; Meagher JL; Stuckey JA; Wang S
J Med Chem; 2012 Oct; 55(19):8502-14. PubMed ID: 23030453
[TBL] [Abstract][Full Text] [Related]
4. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
5. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
6. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor pyrimidinylpiperazines bind to the prosurvival Bcl-2 protein family member Bcl-XL.
Shallal HM; Faridi JS; Russu WA
Bioorg Med Chem Lett; 2011 Mar; 21(5):1325-8. PubMed ID: 21300543
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
10. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
11. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
12. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
Tang G; Yang CY; Nikolovska-Coleska Z; Guo J; Qiu S; Wang R; Gao W; Wang G; Stuckey J; Krajewski K; Jiang S; Roller PP; Wang S
J Med Chem; 2007 Apr; 50(8):1723-6. PubMed ID: 17378545
[TBL] [Abstract][Full Text] [Related]
13. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
Wang G; Nikolovska-Coleska Z; Yang CY; Wang R; Tang G; Guo J; Shangary S; Qiu S; Gao W; Yang D; Meagher J; Stuckey J; Krajewski K; Jiang S; Roller PP; Abaan HO; Tomita Y; Wang S
J Med Chem; 2006 Oct; 49(21):6139-42. PubMed ID: 17034116
[TBL] [Abstract][Full Text] [Related]
15. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Tang Y; Zhang DY; Wu XM
Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
[TBL] [Abstract][Full Text] [Related]
16. Dual Bcl-X
Daguer JP; Gonse A; Shchukin Y; Farrera-Soler L; Barluenga S; Winssinger N
Bioorg Med Chem; 2021 Aug; 44():116282. PubMed ID: 34216984
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
18. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.
Perez HL; Banfi P; Bertrand J; Cai ZW; Grebinski JW; Kim K; Lippy J; Modugno M; Naglich J; Schmidt RJ; Tebben A; Vianello P; Wei DD; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3946-50. PubMed ID: 22608961
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
Li HQ; Yang J; Ma S; Qiao C
Bioorg Med Chem; 2012 Jul; 20(14):4194-200. PubMed ID: 22739087
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
